Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COAST: aHSCT vs Ocrelizumab or Alemtuzumab in Active RRMS
NCT04971005Phase 2Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of autologous hematopoietic stem cells in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Time to treatment failure as assessed by failure of NEDA (no evidence of disease activity) at 2 years. Started Aug 2021; status: terminated.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04971005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971005.